Articles related to RESEARCH & CLINICAL TRIALS

A phase 3 trial comparing doxorubicin-trabectedin combination therapy to doxorubicin alone in advanced leiomyosarcoma patients demonstrated a median overall survival of 33 months versus 24 months, respectively.

The TOPAZ-1 trial demonstrates that adding durvalumab to standard chemotherapy significantly improves overall survival in patients with advanced biliary tract cancer, potentially establishing a new first-line treatment option for this difficult-to-treat malignancy.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.

Actigraphy devices revealed significant improvements in sleep patterns with nighttime levodopa use, despite patients not perceiving these changes subjectively.

Recent studies have identified a range of chemical compounds released by face masks, including microplastics, volatile organic compounds, and plasticizers, prompting a closer examination of potential cumulative exposure risks.

Twice-yearly azithromycin distribution to children aged 1-59 months reduced all-cause mortality by 14% compared to placebo, even in communities with lower baseline mortality rates and ongoing malaria prevention efforts.